Identification of Cystatin SN as a novel tumor marker for colorectal cancer

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 33-40

  Yoneda, Kyoko ^a   Iida, Hiroshi ^a   Endo, Hiroki ^a   Hosono, Kunihiro ^a   Akiyama, Tomoyuki ^a   Takahashi, Hirokazu ^a   Inamori, Masahiko ^a   Abe, Yasunobu ^a   Yoneda, Masato ^a   Fujita, Koji ^a   Kato, Shingo ^a   Nozaki, Yuichi ^a   Ichikawa, Yasushi ^a   Uozaki, Hiroshi ^b   Fukayama, Masashi ^b   Shimamura, Takahiro ^c   Kodama, Tatsuhiko ^c   Aburatani, Hiroyuki ^c   Miyazawa, Chihiro ^d   Ishii, Keisuke ^d   Hosomi, Naoki ^d   Sagara, Mina ^d   Takahashi, Masazumi ^e   Ike, Hideyuki ^f   Saito, Hiroaki ^g   Kusakabe, Akihiko ^g   Nakajima, Atsushi ^a   more..

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Perseus Proteomics   (Japan)

^e YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^f Department of Surgery   (Japan)

^g Yokohama Kosei Hospital   (Japan)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; Cystatin SN; Early detection; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYSTATIN; CYSTATIN SN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; ROC CURVE; SALIVARY CYSTATINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 67649427308     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000310     Document Type: Article

References (23)

1. Ouyang DL, Chen JJ, Getzenberg RH and Schoen RE: Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 100: 1393-1403, 2005.
2. Inger DB: Colorectal cancer screening. Prim Care 26: 179-187, 1999.
3. Collins JF, Lieberman DA, Durbin TE and Weiss DG: Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 142: 81-85, 2005.
4. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351: 2704-2714, 2004.
5. Parekh M, Fendrick AM and Ladabaum U: As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 27: 697-712, 2008.
6. Woolf SH: The best screening test for colorectal cancer-a personal choice. N Engl J Med 343: 1641-1643, 2000.
7. Winawer S, Fletcher R, Rex D, et al: Colorectal cancer screening and surveillance: clinical guidelines and rationale - Update based on new evidence. Gastroenterology 124: 544-560, 2003.
8. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.
9. European Group on Tumour Markers: Tumour markers in gastrointestinal cancers - EGTM recommendations. Anticancer Res 28: 2811-2815, 1999.
10. American Society of Clinical Oncology: 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16: 793-795, 1998.
11. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Järvinen H and Haglund C: Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 66: 296-302, 2004.
12. Tseng CC, Tseng CP, Levine MJ and Bobek LA: Differential effect toward inhibition of papain and cathepsin C by recombinant human salivary cystatin SN and its variants produced by a baculovirus system. Arch Biochem Biophys 380: 133-140, 2000.
13. Midorikawa Y, Tsutsumi S, Taniguchi H, et al: Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res 93: 636-643, 2002.
14. Hippo Y, Taniguchi H, Tsutsumi S, et al: Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62: 233-240, 2002.
15. Tanaka T, Takeno T, Watanabe Y, et al: The generation of monoclonal antibodies against human peroxisome proliferator-activated receptors (PPARs). J Atheroscler Thromb 9: 233-242, 2002.
16. Watanabe Y, Tanaka T, Uchiyama Y, et al: Establishment of a monoclonal antibody for human LXRalpha: Detection of LXRalpha protein expression in human macrophages. Nucl Recept 1: 1, 2003.
17. Watanabe Y, Jiang S, Takabe W, et al: Expression of the LXRalpha protein in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 25: 622-627, 2005.
18. Saitoh R, Ohtomo T, Yamada Y, et al: Viral envelope protein gp64 transgenic mouse facilitates the generation of monoclonal antibodies against exogenous membrane proteins displayed on baculovirus. J Immunol Methods 322: 104-117, 2007.
19. Köhler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
20. Parham P: On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol 131: 2895-2902, 1983.
21. Ishikawa E, Yoshitake S, Imagawa M and Sumiyoshi A: Preparation of monomeric Fab'-horseradish peroxidase conjugate using thiol groups in the hinge and its evaluation in enzyme immunoassay and immunohistochemical staining. Ann NY Acad Sci 420: 74-89, 1983.
22. Link KH, Sagban TA, Mörschel M, et al: Colon cancer: survival after curative surgery. Langenbecks Arch Surg 390: 83-93, 2005.
23. Zweig MH and Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-577, 1993.